PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation.

Insulin signaling is essential for regulating growth and metabolism in animals. Prior research has shown that this pathway senses nutrient availability and modulates downstream effectors like S6K. However, the mechanisms that negatively regulate S6K phosphorylation remain poorly understood. No prior work had resolved whether phosphatases specifically target S6K to counteract insulin signaling. This gap motivated the search for novel regulatory components of the insulin pathway. Researchers have identified several kinases that phosphorylate S6K, but the phosphatases involved in dephosphorylation are less characterized. The role of PP2A in general signaling is known, but its specific subunits targeting S6K are not fully understood. That uncertainty drove this study to investigate the role of PP2A regulatory subunits in S6K regulation. This study addresses a key gap in understanding how S6K activity is balanced in the insulin signaling network.

The aim of this study was to identify novel regulatory components of the insulin signaling pathway that specifically target S6K. The researchers sought to determine whether PP2A regulatory subunits could modulate S6K phosphorylation. They focused on the Drosophila PP2A-B' subunit, which had not been previously linked to insulin signaling. The study aimed to test whether PP2A-B' could dephosphorylate S6K and influence downstream phenotypes. The researchers also investigated whether this mechanism is conserved in mammals. They hypothesized that PP2A-B' might act as a negative regulator of S6K activity. The study aimed to assess the physiological consequences of PP2A-B' knockout in flies. This work sought to clarify the role of PP2A-B' in maintaining metabolic homeostasis through S6K regulation.

The study used Drosophila as a model organism to investigate PP2A-B' function. Researchers generated PP2A-B' knockout flies and analyzed S6K phosphorylation levels. They performed genetic crosses to assess interactions between PP2A-B' and S6K. Protein-protein interactions were tested using co-immunoprecipitation assays. Metabolic parameters such as triglyceride levels and lifespan were measured in knockout flies. The human homolog PPP2R5C was studied using cell culture experiments. Researchers assessed whether PPP2R5C could dephosphorylate S6K1 in human cells. The study combined genetic, biochemical, and physiological approaches to validate the role of PP2A-B'.

PP2A-B' knockout flies exhibited elevated S6K phosphorylation compared to controls. These flies showed reduced triglyceride levels and decreased longevity. The researchers observed phenotypes consistent with hyperactive insulin signaling. PP2A-B' physically interacts with S6K in vivo. Genetic interactions confirmed that PP2A-B' negatively regulates S6K activity. The human homolog PPP2R5C also dephosphorylates S6K1 in mammalian cells. This finding indicates a conserved mechanism across species. The study provides evidence that PP2A-B' is a novel component of the insulin signaling pathway.

The authors propose that PP2A-B' functions as a phosphatase that specifically targets S6K in the insulin signaling pathway. They suggest that PP2A-B' is a conserved regulator of S6K phosphorylation in both flies and humans. The study indicates that PP2A-B' knockout leads to metabolic phenotypes linked to elevated insulin signaling. The researchers conclude that PP2A-B' is necessary for maintaining metabolic homeostasis. They propose that PPP2R5C, the human homolog, may have similar regulatory roles. The data suggest that PP2A-B' is a novel factor in the regulation of S6K activity. The findings highlight the importance of phosphatases in balancing insulin signaling. The authors suggest that further research is needed to explore the therapeutic potential of PPP2R5C.